StockNews.AI
KPTI
StockNews.AI
188 days

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

1. KPTI to report Q4 and 2024 results on February 19, 2025. 2. Management will hold a call to discuss results and updates. 3. Karyopharm focuses on novel cancer therapies and has approved drug XPOVIO®. 4. Their pipeline targets high unmet need cancers like multiple myeloma. 5. XPOVIO® is marketed across the U.S., Europe, and China.

Earnings
+0.82%Current Return
VS
+0.18%S&P 500
$0.598102/12 07:05 AM EDTEvent Start
$0.60302/13 01:41 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

While financial results are crucial, there's no immediate data or news affecting KPTI’s performance. Historical patterns suggest mixed market reactions to earnings announcements.

How important is it?

The earnings report is significant for understanding KPTI's financial health and future prospects. Company performance directly influences investor perception and stock value.

Why Short Term?

Upcoming earnings results could have immediate but limited impact on stock price. Past earnings calls have led to short-lived price changes.

Related Companies

KPTI
-- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- , /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News